Patients will no longer have to provide blood test results before filling their prescription
Performance better for transition to schizophrenia than for bipolar disorder
Schizophrenia-associated increase seen from prelegalization to legalization of nonmedical cannabis periods
Faster diffusion of telemental health care for schizophrenia seen in state-operated versus free-standing mental health agencies
Co-commencement with antipsychotic medications can reduce weight gain by 4.03 kg compared with control
Increased risk for SSD seen within three years for individuals with ED visit for hallucinogen use compared with ED visits for alcohol, cannabis
Findings seen among patients hospitalized long term for schizophrenia
Approval marks first new class of treatment in decades and the first muscarinic agonist
Low rates of treatment observed, with only 26 percent receiving minimally adequate mental health treatment
